Joy Willis - Tryp Therapeutics Director Relations
| TRYPFDelisted Stock | USD 0.05 0 6.89% |
Insider
Joy Willis is Director Relations of Tryp Therapeutics
| Phone | 833 811 8797 |
| Web | https://www.tryptherapeutics.com |
Tryp Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.0512) % which means that it has lost $2.0512 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.2206) %, meaning that it generated substantial loss on money invested by shareholders. Tryp Therapeutics' management efficiency ratios could be used to measure how well Tryp Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA DO | Antibe Therapeutics | 57 | |
| MSc MSc | Cellectis SA | 54 | |
| Kazumi Sawaguchi | SanBio Company Limited | N/A | |
| Barry Kenny | Sosei Group | N/A | |
| MBA MBA | Antibe Therapeutics | N/A | |
| Kieran FCA | Sosei Group | N/A | |
| Greg Gillas | SanBio Company Limited | N/A | |
| ACIS BComm | Pharmather Holdings | 51 | |
| Ana Stegic | Antibe Therapeutics | N/A | |
| Chris Cargill | Sosei Group | 39 | |
| Andrew Liu | SanBio Company Limited | N/A | |
| Yoshihiro Kakutani | SanBio Company Limited | N/A | |
| MEng CFA | Antibe Therapeutics | N/A | |
| Bijan Nejadnik | SanBio Company Limited | 61 | |
| Jean Epinat | Cellectis SA | N/A | |
| Fabio Chianelli | Pharmather Holdings | 45 | |
| Michael McGrogan | SanBio Company Limited | N/A | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Valerie Cros | Cellectis SA | N/A | |
| Candelle Chong | Sosei Group | N/A | |
| LLB JD | Antibe Therapeutics | 65 | |
Management Performance
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 |
Tryp Therapeutics Leadership Team
Elected by the shareholders, the Tryp Therapeutics' board of directors comprises two types of representatives: Tryp Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tryp. The board's role is to monitor Tryp Therapeutics' management team and ensure that shareholders' interests are well served. Tryp Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tryp Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CoFounder Director | ||
| Joy Willis, Director Relations | ||
| Dr MSIB, Pres CEO | ||
| Jim ONeill, Chief Officer | ||
| Sidney RPh, Chief Officer |
Tryp Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Tryp Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Shares Owned By Insiders | 47.24 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Net Income | (7.49 M) | |||
| Cash And Equivalents | 2.85 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |